Immunome (IMNM) Non-Current Assets (2019 - 2026)

Immunome has reported Non-Current Assets for 8 years, with the latest figure at $25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 30.26% year-over-year to $25.5 million; the trailing twelve-month figure through Mar 2026 stood at $86.2 million (up 36.28% YoY), and the FY2025 full-year result was $22.4 million, up 18.56% from the prior year.
• Non-Current Assets for Q1 2026 stood at $25.5 million, up from $22.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $25.5 million in Q1 2026, with the low at $1.3 million in Q3 2022.
• Historically, Non-Current Assets has averaged $10.0 million across 5 years, with a median of $6.4 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets retreated 4.46% — and 2024, when it soared 636.0%.
• Immunome's Non-Current Assets stood at $1.4 million in 2022, then surged by 174.66% to $3.8 million in 2023, then soared by 392.62% to $18.9 million in 2024, then grew by 18.56% to $22.4 million in 2025, then rose by 13.71% to $25.5 million in 2026.
• The last three Non-Current Assets figures came in at $25.5 million (Q1 2026), $22.4 million (Q4 2025), and $19.5 million (Q3 2025), per Business Quant data.